Ricardo Miguel Costa de Freitas

Ricardo Miguel Costa de Freitas

Auto-generated profile, based on publicly available information

Ricardo Miguel Costa de Freitas

Interventional Radiology Unit, Instituto de Radiologia, Hospital das Clínicas, Universidade de São Paulo Medical School, São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
LCLuciana Audi Castroneves
Luciana Audi Castroneves
GFGeorge Coura Filho
George Coura Filho
RFRicardo Miguel Costa de Freitas
Ricardo Miguel Costa de Freitas
RSRaphael Salles
Raphael Salles
RMRaquel Ajub Moyses
Raquel Ajub Moyses
AHAna Oliveira Hoff
Ana Oliveira Hoff
Persistent disease after surgery is common in medullary thyroid cancer (MTC) requiring lifelong radiological surveillance. Staging work-up includes imaging of neck, chest, abdomen and bones. A study integrating all sites would be ideal. Despite the established use of 68Ga PET/CT with somatostatin analogs in most neuroendocrine tumors, in MTC its efficacy is controversial. Objective Evaluate the efficacy of 68Ga PET/CT in detecting MTC lesions and evaluate tumor expression of somatostatin receptors (SSTR) associating with 68Ga PET/CT findings. Methods Prospective study evaluating 30 MTC patients; Group 1 (N=16): Biochemical disease and Group 2 (N=14): Metastatic disease. Patients underwent 68Ga PET/CT, bone scan, neck CT and US, CT chest, CT/MRI abdomen, MRI spine. 68Ga PET/CT findings were analyzed by disease site as positive or negative and as concordant or discordant with conventional studies. Sensitivity and specificity were calculated using pathological, cytological analysis or unequivocal identification by standard imaging studies. Immunohistochemical analysis of SSTRs were compared with 68Ga PET/CT findings. Results In both groups 68Ga PET/CT was inferior than currently used imaging studies except for bone scan. In group 2, 68Ga PET/CT sensitivities were 56%, 57% and 9% for detecting neck lymph nodes, lung and liver metastases and 100% for bone metastases, superior than bone scan (44%). Expression of SSTRs, observed in 44% of tumors, was not associated with68Ga DOTATATE uptake. Conclusions 68Ga PET/CT does not provide optimal whole-body imaging as a single procedure in patients with MTC. However, is highly sensitive detecting bone lesions and could substitute bone scan and MRI.

1 March 2016 in Thyroid®
Verified
Journal Article
Closed access
LCLuciana Audi de Castroneves
Luciana Audi de Castroneves
MNMarcelo Vailati Negrão
Marcelo Vailati Negrão
RFRicardo Miguel Costa de Freitas
Ricardo Miguel Costa de Freitas
CPCarla Papadia
Carla Papadia
JLJosé Viana Lima
José Viana Lima
AHAna Oliveira Hoff
Ana Oliveira Hoff
Background: Treatment of advanced medullary thyroid carcinoma (MTC) was recently improved with the approval of vandetanib and cabozantinib. However, there is still a need to explore sequential therapy with more than one tyrosine kinase inhibitor (TKI) and to explore alternative therapies when vandetanib and cabozantinib are not available. This study reports the authors' experience with sorafenib as a treatment for advanced MTC. Methods: This is a retrospective longitudinal study of 13 patients with progressive metastatic MTC treated with sorafenib 400 mg twice daily between December 2011 and January 2015. The primary endpoints were to evaluate response and progression-free survival (PFS) in patients treated with sorafenib outside a clinical trial. The secondary endpoint was an assessment of the toxicity profile. One patient was excluded because of a serious allergic skin rash one week after starting sorafenib. Results: The analysis included 12 patients with metastatic MTC (median age 48 years), 10 with sporadic and 2 with hereditary disease. The median duration of treatment was 11 months, and the median follow-up was 15.5 months. At data cutoff, 2/12 (16%) patients were still on treatment for 16 and 34 months. According to Response Evaluation Criteria in Solid Tumors analysis, 10 (83.3%) patients showed stable disease, and two (16.6%) had progression of disease; no partial response was observed. The median PFS was nine months. However, three patients with extensive and rapidly progressive disease died within three months of sorafenib treatment. The median PFS excluding these three patients was 12 months. Adverse events (AE) occurred in nine (75%) patients. The main AEs were skin toxicity, weight loss, and fatigue. Five (41.6%) patients needed dose reduction, and one patient discontinued treatment because of toxicity. Conclusions: Treatment with sorafenib in progressive metastatic MTC is well tolerated and resulted in disease control and durable clinical benefit in 75% of patients. Sorafenib treatment could be considered when vandetanib and cabozantinib are not available or after failing these drugs.

19 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Amanda LacombeAmanda Lacombe
Amanda Lacombe
ISIberê Cauduro Soares
Iberê Cauduro Soares
BMBeatriz Marinho de Paula Mariani
Beatriz Marinho de Paula Mariani
MNMirian Yumie NISHI
Mirian Yumie NISHI
JNJoao Evangelista Bezerra Neto
Joao Evangelista Bezerra Neto
MFMaria Candida B. V. Fragoso
Maria Candida B. V. Fragoso
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with an unfavorable prognosis. Despite the poor prognosis in the majority of patients, no improvements in treatment strategies have been achieved. Therefore, the discovery of new prognostic biomarkers is of enormous interest. Sterol-O-acyl transferase 1 (SOAT1) is involved in cholesterol esterification and lipid droplet formation. Recently, it was demonstrated that SOAT1 inhibition leads to impaired steroidogenesis and cell viability in ACC. To date, no studies have addressed the impact of SOAT1 expression on ACC prognosis and clinical outcomes. We evaluated SOAT1 expression by quantitative real-time polymerase chain reaction and immunohistochemistry in a tissue microarray of 112 ACCs (Weiss score ≥ 3) from adults treated in a single tertiary center in Brazil. Two independent pathologists evaluated the immunohistochemistry results through a semiquantitative approach (0–4). We aimed to evaluate the correlation between SOAT1 expression and clinical, biochemical and anatomopathological parameters, recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS). SOAT1 protein expression was heterogeneous in this cohort, 37.5% of the ACCs demonstrated a strong SOAT1 protein expression (score > 2), while 62.5% demonstrated a weak or absent protein expression (score ≤ 2). Strong SOAT1 protein expression correlated with features of high aggressiveness in ACC, such as excessive tumor cortisol secretion (p = 0.01), an advanced disease stage [European Network for the Study of Adrenal Tumors (ENSAT) staging system 3 and 4 (p = 0.011)] and a high Ki67 index (p = 0.002). In multivariate analysis, strong SOAT1 protein expression was an independent predictor of a reduced OS (hazard ratio (HR) 2.15, confidence interval (CI) 95% 1.26–3.66; p = 0.005) in all patients (n = 112), and a reduced RFS (HR 2.1, CI 95% 1.09–4.06; p = 0.027) in patients with localized disease at diagnosis (n = 83). Our findings demonstrated that SOAT1 protein expression has prognostic value in ACC and reinforced the importance of investigating SOAT1 as a possible therapeutic target for patients with ACC.

7 May 2018 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
DDDebora L. S. Danilovic
Debora L. S. Danilovic
GCGilberto Castro
Gilberto Castro
FRFelipe S. R. Roitberg
Felipe S. R. Roitberg
FVFelipe A. B. Vanderlei
Felipe A. B. Vanderlei
FBFernanda A. Bonani
Fernanda A. Bonani
AHAna O. Hoff
Ana O. Hoff
Total thyroidectomy, radioiodine (RAI) therapy, and TSH suppression are the mainstay treatment for differentiated thyroid carcinomas (DTCs). Treatments for metastatic disease include surgery, external-beam radiotherapy, RAI, and kinase inhibitors for progressive iodine-refractory disease. Unresectable locoregional disease remains a challenge, as standard therapy with RAI becomes unfeasible. We report a case of a young patient who presented with unresectable papillary thyroid carcinoma (PTC), and treatment with sorafenib allowed total thyroidectomy and RAI therapy. A 20-year-old male presented with severe respiratory distress due to an enlarging cervical mass. Imaging studies revealed an enlarged multinodular thyroid gland, extensive cervical adenopathy, severe tracheal stenosis, and pulmonary micronodules. He required an urgent surgical intervention and underwent tracheostomy and partial left neck dissection, as the disease was deemed unresectable; pathology revealed PTC. Treatment with sorafenib was initiated, resulting in significant tumor reduction allowing near total thyroidectomy and bilateral neck dissection. Postoperatively, the patient underwent radiotherapy for residual tracheal lesion, followed by RAI therapy for avid cervical and pulmonary disease. The patient's disease remains stable 4 years after diagnosis. Sorafenib has been approved for progressive RAI-refractory metastatic DTCs. In this case report, we describe a patient with locally advanced PTC in whom treatment with sorafenib provided sufficient tumor reduction to allow thyroidectomy and RAI therapy, suggesting a potential role of sorafenib as an induction therapy of unresectable DTC.

25 July 2019 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
RFRicardo Miguel Costa de Freitas
Ricardo Miguel Costa de Freitas
AMAline Paterno Miazaki
Aline Paterno Miazaki
MTMiriam Harumi Tsunemi
Miriam Harumi Tsunemi
VFVergilius José Furtado de Araujo Filho
Vergilius José Furtado de Araujo Filho
SMSuemi Marui
Suemi Marui
MCMaria Cristina Chammas
Maria Cristina Chammas

1 December 2010 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
RFRicardo Miguel Costa de Freitas
Ricardo Miguel Costa de Freitas
RPRenata Prado
Renata Prado
FPFábio Luis Silva Do Prado
Fábio Luis Silva Do Prado
IPIvie Braga de Paula
Ivie Braga de Paula
MFMarco Túlio Alves Figueiredo
Marco Túlio Alves Figueiredo
EPEnio Roberto Pietra Pedroso
Enio Roberto Pietra Pedroso
INTRODUCTION: The purpose of this study was to compare respiratory signs and symptoms between patients with and without chest X-ray abnormalities in order to establish the meaning of radiographic findings in pulmonary PCM diagnosis. METHODS: The epidemiological, clinical and radiological lung findings of 44 patients with paracoccidiodomycosis (PCM) were evaluated. Patients were divided into two groups of 23 and 21 individuals according to the presence (group 1) or absence (group 2) of chest X-ray abnormalities, respectively, and their clinical data was analyzed with the aid of statistical tools. RESULTS: As a general rule, patients were rural workers, young adult males and smokers - group 1 and 2, respectively: males (91.3% and 66.7%); mean age (44.4 and 27.9 year-old); smoking (34.7% and 71.4 %); acute/subacute presentation (38.1% and 21.7%); chronic presentation (61.9% and 78.3%). The most frequent respiratory manifestations were - group 1 and 2, respectively: cough (25% and 11.4%) and dyspnea (22.7% and 6.8%). No statistical difference was observed in pulmonary signs and symptoms between patients with or without radiographic abnormalities. The most frequent radiological finding was nodular (23.8%) or nodular-fibrous (19%), bilateral (90.5%) and diffuse infiltrates (85.7%). CONCLUSIONS: Absence of statistical difference in pulmonary signs and symptoms between these two groups of patients with PCM indicates clinical-radiological dissociation. A simplified classification of radiological lung PCM findings is suggested, based on correlation of these data and current literature review.